neonat
sepsi
septicaemia
clinic
syndrom
character
system
sign
circulatori
compromis
eg
poor
peripher
perfus
pallor
hypotonia
poor
respons
caus
invas
bloodstream
bacteria
first
month
life
preantibiot
era
neonat
sepsi
usual
fatal
case
fatal
rate
antibiot
treat
infant
rang
highest
rate
report
lowestincom
countri
world
health
organ
estim
million
death
per
year
underf
mortal
due
neonat
sepsi
death
occur
first
week
life
wide
dispar
neonat
care
highand
lowincom
countri
highincom
countri
major
concern
increas
number
extrem
prematur
infant
high
nosocomi
infect
rate
due
multiresist
organ
intens
care
unit
health
facil
infect
also
major
problem
lowincom
countri
press
issu
high
proport
home
deliveri
unclean
environ
predispos
sepsi
ensur
neonat
access
effect
intervent
health
care
provid
first
day
life
inde
new
strategi
prevent
diagnos
treat
neonat
sepsi
need
lowand
highincom
set
distal
risk
factor
neonat
sepsi
includ
poverti
poor
environment
condit
proxim
factor
includ
prolong
ruptur
membran
preterm
labour
matern
pyrexia
unhygien
intrapartum
postnat
care
low
birth
weight
prelact
feed
contamin
food
fluid
bacteria
caus
neonat
sepsi
acquir
shortli
deliveri
figur
obtain
directli
mother
blood
skin
vagin
tract
deliveri
environ
deliveri
streptococcu
agalactia
group
b
streptococcu
gb
common
caus
neonat
sepsi
mani
countri
though
low
rate
report
mani
lowincom
countri
especi
south
asia
gramneg
bacilli
escherichia
coli
klebsiella
spp
pseudomona
spp
acinetobact
spp
gramposit
cocci
staphylococcu
aureu
staphylococcu
epidermidi
import
caus
howev
mani
difficulti
interpret
aetiolog
neonat
sepsi
data
mani
studi
report
select
popul
highrisk
infant
specimen
infant
first
hour
life
also
serious
underrepres
especi
low
birthweight
babi
babi
born
outsid
health
facil
intrapartum
antibiot
prophylaxi
agalactia
also
led
substanti
chang
bacteria
respons
earli
onset
neonat
sepsi
gramneg
bacilli
staphylococcu
spp
predomin
countri
implement
program
also
mani
import
neonat
infecti
diseas
pathogen
associ
sepsi
syndrom
includ
treponema
pallidum
rubella
viru
herp
simplex
viru
cytomegaloviru
toxoplasmosi
clostridium
tetani
hiv
hepat
b
viru
bordetella
pertussi
figur
infecti
pathogen
caus
seriou
morbid
young
infant
multifacet
diseas
syndrom
includ
congenit
anomali
development
disabl
chronic
liver
diseas
neonat
tetanu
apnoea
also
import
caus
morbid
mortal
older
age
group
howev
pathogen
caus
neonat
sepsi
discuss
paper
neonat
function
immatur
immun
system
extrem
low
immunoglobulin
ig
level
except
igg
specif
matern
antigen
transfer
passiv
across
placenta
last
trimest
pregnanc
cell
function
rel
unimpair
complement
activ
half
healthi
adult
neonat
low
neutrophil
storag
pool
exist
neutrophil
impair
capac
migrat
blood
site
infect
basal
express
tolllik
receptor
tlr
receptor
detect
presenc
microb
similar
neonat
adult
howev
innat
immun
respons
neonat
mononuclear
cell
characteris
markedli
reduc
releas
proinflammatori
cytokin
tumour
necrosi
factoralpha
tnfa
interferongamma
ifnc
rel
preserv
antiinflammatori
cytokin
interleukin
find
may
reflect
utero
requir
includ
avoid
harm
inflammatori
immun
reaction
immunolog
problem
reflect
clinic
present
neonat
sepsi
neonat
rapid
fulmin
progress
septicaem
diseas
nonspecif
clinic
sign
infect
difficulttointerpret
laboratori
result
includ
haematolog
immunolog
biomark
infect
inflamm
low
birthweight
preterm
small
gestat
age
infant
even
poorer
function
immun
especi
risk
sepsi
howev
neonat
wellfunct
cation
membraneact
antimicrobi
protein
peptid
app
microbicid
properti
app
found
vernix
caseosa
cover
skin
birth
neonat
gastrointestin
respiratori
tract
mani
older
studi
demonstr
improv
matern
health
nutrit
deliveri
directli
associ
improv
neonat
health
outcom
randomis
control
trial
rct
matern
proteincalori
multipl
micronutri
supplement
demonstr
signific
improv
rate
prematur
birth
weight
variabl
impact
mortal
studi
examin
impact
rate
neonat
sepsi
matern
immunis
import
method
provid
neonat
appropri
antibodi
soon
born
approach
less
sensit
obstacl
access
health
care
system
approach
exampl
success
intervent
includ
matern
tetanu
toxoid
influenza
immunis
studi
matern
immunis
agalactia
type
iii
conjug
vaccin
demonstr
excel
placent
transfer
persist
protect
level
infant
phase
ii
trial
serotyp
nonpregn
women
also
demonstr
safeti
immunogen
recent
model
studi
estim
vaccin
agalactia
vaccin
would
prevent
us
preterm
birth
neonat
agalactia
infect
encourag
result
also
emerg
studi
matern
immunis
pneumococc
polysaccharid
conjug
vaccin
vaccin
excel
safeti
profil
howev
barrier
matern
immunis
includ
liabil
issu
vaccin
manufactur
develop
countri
educ
public
health
care
provid
regard
benefit
matern
immunis
poor
ascertain
data
lowincom
countri
strong
evid
clean
deliveri
practic
handwash
deliveri
reduc
rate
neonat
sepsi
home
health
facil
set
intervent
improv
handwash
rate
remark
success
research
set
reason
lack
success
scaleup
handwash
intervent
polici
program
behaviour
chang
less
clear
new
studi
malawi
nepal
indic
matern
antisepsi
intervent
vagin
chlorhexidin
labour
may
signific
impact
rate
neonat
mortal
sepsi
develop
countri
howev
studi
highincom
countri
demonstr
littl
effect
rate
hiv
neonat
infect
intrapartum
antibiot
prophylaxi
highli
effect
reduc
earlyonset
neonat
bacteri
matern
sepsi
develop
countri
chemoprophylaxi
us
halv
incid
earlyonset
neonat
bacteri
sepsi
caus
agalactia
per
live
birth
per
clear
protocol
place
highincom
countri
manag
women
risk
factor
neonat
sepsi
risk
factor
earlyonset
neonat
bacteri
sepsi
lowincom
set
probabl
similar
resourcerich
set
evalu
context
high
rate
matern
undernutrit
anaemia
hiv
malaria
also
strong
evid
handwash
health
care
provid
deliveri
reduc
neonat
sepsi
infect
rate
especi
hospit
less
evid
import
rigor
handwash
use
antisept
mother
infant
five
key
paper
prevent
diagnos
treat
neonat
sepsi
highincom
set
studi
shown
advantag
antibiot
antisept
simpli
keep
umbil
cord
clean
howev
umbil
stump
chlorhexidin
cleans
recent
shown
substanti
reduc
neonat
death
nepal
studi
investig
effect
chlorhexidin
prevent
omphal
current
underway
sever
countri
emerg
evid
neonat
skin
antisepsi
prepar
sunflow
seed
oil
provid
cheap
safe
effect
protect
nosocomi
infect
hospit
preterm
neonat
infant
studi
south
asia
applic
chlorhexidin
neonat
skin
also
shown
effect
reduc
neonat
sepsi
studi
south
asia
neonat
immunis
long
consid
import
method
reduc
neonat
infect
howev
respons
vari
accord
antigen
bcg
polio
hepat
b
vaccin
highli
immunogen
given
birth
howev
matern
antibodi
interfer
neonat
respons
measl
vaccin
administ
six
month
protein
antigen
vaccin
eg
pertussi
tetanu
toxoid
given
birth
shown
produc
poor
respons
compar
antigen
given
two
month
age
associ
later
toler
studi
also
indic
agalactia
streptococcu
pneumonia
vaccin
like
ineffect
given
neonat
period
breastmilk
contain
secretori
iga
lysozym
white
blood
cell
lactoferrin
shown
encourag
growth
healthi
lactobacilli
reduc
growth
e
coli
gramneg
pathogen
bacteria
rct
focus
increas
earli
initi
exclus
breastfeed
rate
demonstr
signific
reduct
diarrhoea
acut
respiratori
infect
neonat
older
infant
india
observ
studi
demonstr
impact
infect
specif
mortal
rate
allcaus
mortal
neonat
period
neonat
micronutri
supplement
trial
focus
vitamin
supplement
older
studi
shown
signific
reduct
respiratori
diseas
low
birthweight
infant
administr
parenter
vitamin
recent
trial
newborn
vitamin
supplement
shown
encourag
reduct
neonat
mortal
trial
underway
highincom
countri
clinic
trial
immun
stimul
granulocyt
monocyt
coloni
stimul
factor
gmcsf
enhanc
quantiti
qualiti
neonat
neutrophil
monocyt
appear
promis
yet
shown
signific
clinic
benefit
evalu
recombin
app
adjunct
therapi
neonat
infect
still
evalu
impact
tlr
agonist
improv
defenc
microorgan
also
evalu
neonat
clinic
sepsi
syndrom
identif
difficult
clinic
sign
neonat
septicaemia
similar
lifethreaten
diseas
necrotis
enterocol
hyalin
membran
diseas
perinat
asphyxia
howev
recent
studi
middleand
lowincom
countri
provid
seven
danger
sign
use
identifi
infant
sever
diseas
includ
neonat
sepsi
tabl
sign
provid
high
sensit
moder
specif
detect
seriou
ill
newborn
lowresourc
set
incorpor
new
neonat
integr
manag
childhood
ill
nimci
guidelin
identif
neonat
sepsi
deliveri
also
remain
challeng
combin
matern
risk
factor
clinic
sign
symptom
current
use
howev
peripartum
proteom
analysi
amniot
fluid
offer
opportun
earli
accur
diagnosi
earlyonset
neonat
sepsi
select
popul
women
undergo
amniocentesi
highrisk
pregnanc
confirm
pathogen
organ
allow
target
antibiot
therapi
howev
identif
pathogen
organ
neonat
sepsi
syndrom
fraught
difficulti
bacteri
load
may
low
due
mother
receiv
antepartum
intrapartum
antibiot
small
amount
blood
often
taken
newborn
contamin
rate
may
also
high
due
technic
difficulti
steril
venipunctur
small
babi
may
also
misinterpret
role
coagulaseneg
staphylococci
eg
epidermidi
organ
normal
skin
flora
pathogen
organ
preterm
infant
indwel
blood
vessel
cathet
autom
blood
cultur
system
long
consid
gold
standard
microbiolog
diagnosi
howev
despit
improv
growth
media
instrument
result
blood
cultur
delay
hour
condit
neonat
true
sepsi
deterior
quickli
thu
common
approach
initi
empir
broadspectrum
antibiot
therapi
young
infant
suspect
bacteri
infect
neg
blood
cultur
hour
may
allow
cessat
antibiot
therapi
well
infant
appropri
cautiou
practic
lead
antibiot
exposur
larg
number
newborn
antibiot
treatment
may
unnecessari
sinc
blood
cultur
posit
suspect
sepsi
case
even
highli
resourc
facil
antigen
detect
techniqu
allow
rapid
detect
identif
microorgan
without
cultur
commonli
use
commerci
avail
test
latex
agglutin
assay
base
specif
agglutin
bacteri
cell
wall
antigen
antibodyco
latex
particl
howev
test
detect
specif
organ
agalactia
associ
high
fals
posit
neg
rate
new
urinari
antigen
test
pneumococcu
encourag
also
associ
fals
posit
pneumococc
carriag
polymeras
chain
reaction
pcr
wide
use
biomed
research
laboratori
pathogen
identif
neonat
sepsi
clinic
hospit
laboratori
high
sensit
pcr
allow
detect
bacteri
dna
even
concentr
low
convent
assay
replac
newer
realtim
system
faster
associ
lower
contamin
rate
amplif
detect
occur
simultan
close
system
realtim
pcr
base
measur
fluoresc
signal
gener
amplif
cycl
produc
quantit
result
within
minut
calcul
bacteri
load
broadrang
realtim
pcr
use
singl
primer
detect
univers
bacteri
genom
rna
rna
conserv
ribosom
genom
sequenc
across
bacteri
genera
broadrang
realtim
pcr
use
distinguish
bacteri
septicaem
diseas
caus
neonat
ill
asphyxia
complic
prematur
howev
use
vari
success
analysi
whole
blood
neonat
sepsi
specif
gener
high
sensit
low
contrast
multiplex
pcr
involv
parallel
amplif
differ
target
focus
specif
pathogen
fals
neg
occur
aetiolog
agent
interest
includ
databas
realtim
pcr
often
use
screen
microbi
load
follow
sequencebas
target
identif
pcr
amplicon
pyrosequenc
process
detect
small
copi
number
specif
nucleic
acid
sequenc
also
new
commerci
avail
multiplex
pyrosequenc
pcr
assay
identifi
differ
bacteri
fungal
pathogen
directli
whole
blood
realtim
pcr
pyrosequenc
univers
rrna
gene
also
recent
use
success
neonat
blood
cultur
sampl
test
neonat
whole
blood
plan
number
differ
research
group
biggest
problem
real
time
pcr
test
specimen
must
collect
steril
venipunctur
may
difficult
young
neonat
neonat
capillari
heel
prick
specimen
easier
collect
highli
contamin
skin
flora
also
high
potenti
contamin
enrich
media
reagent
sampl
collect
process
problem
includ
low
sensit
due
competit
human
dna
whole
blood
especi
white
cell
count
high
also
bacteri
organ
requir
lysi
dna
avail
analysi
gramposit
organ
difficult
lyse
resili
cell
wall
realtim
pcr
technolog
also
expens
current
use
highli
train
staff
import
haematolog
test
includ
microscop
examin
blood
white
cell
total
leucocyt
count
differenti
neutrophil
count
immatur
neutrophil
total
neutrophil
ratio
advantag
specimen
requir
steril
heel
prick
specimen
use
howev
mani
indic
fals
low
septic
neonat
biolog
biomark
human
blood
compon
increas
respons
infect
commonli
use
acut
phase
reactant
creactiv
protein
crp
howev
crp
take
hour
increas
measur
level
half
life
long
take
day
normal
erad
infecti
agent
cytokin
tnfa
procalcitonin
also
extens
studi
cytokin
rise
quickli
infect
even
neonat
sensit
low
concentra
tion
pathogen
crp
howev
cord
postnat
blood
cytokin
concentr
depress
presenc
pregnancyinduc
hypertens
rise
induc
vagin
urgent
cesarean
deliveri
deliveri
room
intub
muscular
damag
inflamm
caus
simultan
measur
multipl
biomark
may
improv
sensit
specif
howev
biomark
assay
like
less
accept
physician
often
place
higher
valu
test
confirm
biolog
agent
allow
target
antibiot
therapi
microtechnolog
especi
microfluid
provid
greatest
recent
contribut
diagnosi
neonat
sepsi
microfluid
studi
behaviour
precis
control
manipul
fluid
geometr
constrain
submillimetr
nanolitr
picolitr
channel
microfluid
technolog
use
uniqu
proprieti
continu
flow
microvolum
channel
viscos
surfac
tension
energi
dissip
fluidic
resist
also
includ
micro
pneumat
pump
valv
system
one
specif
applic
microfluid
bacteri
dna
protein
microarray
hybrid
test
dna
probe
specif
select
target
spot
glass
silicon
slide
known
order
target
dna
fragment
label
report
molecul
combin
singl
hybrid
measur
use
fluoresc
signal
techniqu
use
identif
specif
sepsi
pathogen
bacteri
mening
acut
viral
respiratori
tract
infect
neonat
sepsi
also
detect
antimicrobi
resist
virul
gene
research
set
microfluid
technolog
also
allow
sampl
prepar
number
differ
assay
combin
small
dispos
singleus
diagnost
cartridg
card
call
lab
onachip
loc
figur
loc
combin
sampl
prepar
biomark
realtim
pcr
dna
microarray
provid
inform
indic
inflamm
pathogen
identif
antimicrobi
suscept
pattern
point
care
loc
report
perform
assay
sensit
specif
reproduc
level
similar
central
laboratori
analys
yet
requir
littl
user
input
insert
sampl
singl
drop
blood
faec
saliva
test
encourag
result
loc
current
evalu
use
sepsi
endocard
hiv
tuberculosi
sever
acut
respiratori
syndrom
sar
pneumonia
howev
yet
clinic
use
licens
regulatori
author
neonat
sepsi
rapidli
fatal
left
untreat
highli
effect
antibiot
therapi
must
use
delay
provis
care
must
minimis
treatment
must
effect
caus
pathogen
safe
newborn
feasibl
deliv
reliabl
hospit
commun
set
parenter
intraven
intramuscular
regimen
neonat
sepsi
current
recommend
nation
paediatr
associ
combin
penicillin
ampicillin
gentamicin
thirdgener
cephalosporin
eg
ceftriaxon
cefotaxim
day
antibiot
safe
retain
efficaci
administ
extend
interv
eg
twice
daili
daili
dose
regimen
effect
streptococcu
spp
staphylococcu
spp
highli
resist
gramneg
antimicrobi
suscept
ampicillin
gentamicin
also
poor
especi
klebsiella
spp
emerg
e
coli
resist
ampicillin
gentamicin
thirdgener
cephalosporin
hospit
nurseri
develop
develop
countri
also
caus
increas
concern
potenti
signific
lifethreaten
toxic
among
neonat
associ
chloramphenicol
make
least
prefer
empir
parenter
therapi
oral
antibiot
therapi
must
consid
set
referr
possibl
health
care
provid
train
give
parenter
antibiot
increment
benefit
inject
oral
antibiot
known
oral
antibiot
therapi
better
antibiot
therapi
seri
trial
current
evalu
impact
home
clinicbas
short
cours
day
intramuscular
oral
antibiot
therapi
neonat
sepsi
lowincom
countri
data
avail
effect
oral
cotrimoxazol
communitybas
treatment
seriou
neonat
bacteri
infect
nepal
india
howev
concern
high
resist
rate
side
effect
neonat
jaundic
report
oral
amoxicillin
highli
efficaci
streptococcu
spp
gramneg
bacilli
excel
safeti
record
howev
antistaphylococcu
coverag
resist
emerg
gramneg
bacilli
e
coli
new
betterabsorb
oral
antibiot
also
consid
new
secondgener
cephalosporin
eg
cefadroxil
cefuroxim
excel
safeti
profil
spectrum
activ
similar
cotrimoxazol
may
effect
given
high
resist
neonat
pathogen
cotrimoxazol
ciprofloxacin
also
increasingli
accept
safe
neonat
warrant
investig
treatment
infect
newborn
howev
current
cost
agent
potenti
exacerb
antimicrobi
resist
may
limit
widespread
use
develop
countri
poor
maternalneonat
health
system
low
level
careseek
lack
access
sick
newborn
first
day
life
mortal
risk
highest
also
import
concern
recent
studi
shown
commun
health
worker
deliv
antibiot
treatment
neonat
sever
infect
home
safe
accept
hospit
feasibl
trial
current
evalu
effect
qualiti
care
coverag
commun
health
worker
programm
asia
africa
barrier
largescal
implement
includ
high
cost
poor
staff
train
retent
difficulti
referr
eg
lack
ambul
poor
institut
link
newborn
sepsi
major
caus
child
mortal
across
world
industri
countri
made
remark
progress
reduc
newborn
sepsi
sepsisrel
mortal
provid
access
hygien
skill
deliveri
women
riskbas
intrapartum
antibiot
prophylaxi
highqual
intens
care
newborn
need
although
resourc
constraint
preclud
wholescal
adopt
strategi
develop
countri
number
lowcost
proven
intervent
promis
approach
potenti
significantli
reduc
burden
neonat
sepsi
worldwid
tabl
howev
practic
implement
new
advanc
must
consid
skill
attend
deliveri
increas
lowand
middleincom
countri
thu
intrapartum
approach
riskbas
antibiot
prophylaxi
improv
hand
wash
deliveri
like
costeffect
feasibl
countri
challeng
face
implement
diagnost
technolog
may
take
mani
year
technolog
labonachip
suffici
robust
afford
scaleup
lowincom
countri
homebas
antibiot
treatment
neonat
sepsi
also
face
major
obstacl
largescal
implement
concern
one
law
rich
anoth
poor
alreadi
rais
care
assess
risk
benefit
new
technolog
intervent
clearli
need
lowincom
set
also
difficulti
careseek
neonat
ill
home
visit
program
need
identifi
sick
newborn
earli
life
neonat
sepsi
also
one
rapidli
fulmin
clinic
diseas
mani
practition
includ
experienc
neonatologist
administ
parenter
antibiot
rather
wait
result
diagnost
test
practition
rightli
consid
individu
patient
health
import
potenti
risk
emerg
antibiot
resist
thu
frontlin
health
worker
famili
must
partner
research
evalu
plan
detail
assess
endus
attitud
prefer
use
form
qualit
research
method
must
includ
develop
program
reduc
morbid
mortal
neonat
sepsi
final
advocaci
equit
resourc
alloc
across
within
countri
must
prioriti
model
techniqu
assess
public
health
impact
neonat
sepsi
intervent
must
develop
use
wide
icmj
criteria
authorship
read
met
ke
az
agre
manuscript
result
conclus
ke
az
design
experimentsth
studi
ke
az
analyz
data
ke
az
collect
datadid
experi
studi
ke
az
wrote
first
draft
paper
ke
contribut
write
paper
ke
az
